CN101229188A - External medicine for onychomycosis - Google Patents
External medicine for onychomycosis Download PDFInfo
- Publication number
- CN101229188A CN101229188A CNA2008100639768A CN200810063976A CN101229188A CN 101229188 A CN101229188 A CN 101229188A CN A2008100639768 A CNA2008100639768 A CN A2008100639768A CN 200810063976 A CN200810063976 A CN 200810063976A CN 101229188 A CN101229188 A CN 101229188A
- Authority
- CN
- China
- Prior art keywords
- parts
- used medicine
- medicine
- external used
- tinea unguium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 50
- 208000010195 Onychomycosis Diseases 0.000 title claims abstract description 39
- 201000005882 tinea unguium Diseases 0.000 title claims abstract description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 14
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229960001138 acetylsalicylic acid Drugs 0.000 claims abstract description 13
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 claims description 16
- 229920000153 Povidone-iodine Polymers 0.000 claims description 16
- 229960001621 povidone-iodine Drugs 0.000 claims description 16
- 230000000694 effects Effects 0.000 abstract description 5
- 241000233866 Fungi Species 0.000 abstract description 4
- 239000002202 Polyethylene glycol Substances 0.000 abstract description 2
- 229920001223 polyethylene glycol Polymers 0.000 abstract description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- NNYBQONXHNTVIJ-UHFFFAOYSA-N etodolac Chemical compound C1COC(CC)(CC(O)=O)C2=C1C(C=CC=C1CC)=C1N2 NNYBQONXHNTVIJ-UHFFFAOYSA-N 0.000 abstract 1
- 229940063718 lodine Drugs 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 229940069328 povidone Drugs 0.000 abstract 1
- 208000002474 Tinea Diseases 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 206010005913 Body tinea Diseases 0.000 description 4
- 208000007712 Tinea Versicolor Diseases 0.000 description 4
- 206010056131 Tinea versicolour Diseases 0.000 description 4
- 201000003875 tinea corporis Diseases 0.000 description 4
- 201000004647 tinea pedis Diseases 0.000 description 4
- 210000004906 toe nail Anatomy 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 3
- 206010067197 Tinea manuum Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 2
- 210000004905 finger nail Anatomy 0.000 description 2
- 210000000282 nail Anatomy 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000002791 soaking Methods 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 241000130764 Tinea Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides an externally used medicine for onychomycosis treatment, relating to a medicine of treating onychomycosis. The invention solves the problems that seepage force to nail plates of the externally used medicine in the prior art, which cannot seep into the bottom or the deep level of the nail plate to kill fungi. The invention is prepared by mixing the following components by weight portions: povidone lodine of 24 to 36 portions, aspirin of 96 to 144 portions, polyethylene glycol of 44 to 68 portions, ethanol of 400, 480 to 720 portions and water of 91 to 137 portions. The externally used medicine for treating onychomycosis of the invention has the advantages of large seepage force and good treatment effects for onychomycosis, without recurrence after cure.
Description
Technical field
The present invention relates to a kind of medicine for the treatment of tinea unguium.
Background technology
The external used medicine of existing treatment tinea unguium (ash refers to/toenail) is relatively poor to the penetration on deck, can not be penetrated under the first or deck deep layer kill fungi, so drug effect is slow after the medication, and easily recurrence; Also have some external used medicines to contain hormone, toxic and side effects is big.
Summary of the invention
The present invention is poor to the penetration on deck for the external used medicine that solves existing treatment tinea unguium, can not be penetrated into the problem of under the first or deck deep layer kill fungi, and a kind of external used medicine for the treatment of tinea unguium is provided.
The external used medicine that the present invention treats tinea unguium is to be made up of 21～39 parts povidone iodine, 84～156 parts aspirin, 39～75 parts PEG400,420～780 parts ethanol and 80～149 parts water mixing according to weight portion.
The contained povidone iodine of the present invention can progressively discharge iodine and bring into play bactericidal action, and its mechanism of action is to make antibacterial death after the bacterium protein degeneration, and is all effective to antibacterial, fungus and virus.The salicylic acid that aspirin decomposes the back generation has antiinflammatory and itching-relieving action, also has the infiltrative effect of horny layer softening, enhancing medicine.Ethanol can increase medicine to deck and cuticular penetration capacity.
The present invention is different with the external used medicine of existing treatment tinea unguium, uses Polyethylene Glycol as cosolvent in prescription, uses a certain amount of ethanol simultaneously, has increased drug permeability, has promoted the Transdermal absorption effect of povidone iodine.The external used medicine and the existing external used medicine for the treatment of tinea unguium of the present invention being treated tinea unguium carry out mice Transdermal absorption contrast test, the result shows: the mean transmissivity of medicine of the present invention was 1.92% when the mean transmissivity of medicine of the present invention was 0.24%, 240 minute in the time of 30 minutes; And the transmitance of the external used medicine of existing treatment tinea unguium is 0 (transmitance=povidone iodine amount of recording/test consumption), is used to test the mice of medicine transmitance of the present invention and have no adverse reaction.Result of the test shows that drug permeability of the present invention is good, avirulence.
Like product is compared on the products and marketing of the present invention, and following advantage is arranged:
1, the present invention is coated on the deck and can forms a skim, adheres to certain hour above deck, keeps drug effect.
2, povidone iodine is dissolved in the ethanol, increases this medicine to the cuticular penetration power in deck, helps medicinal liquid and is penetrated at the bottom of the first or deep layer kill pathogens at the bottom of the first.
3, the present invention treat tinea unguium external used medicine in use, can be coated with put on the skin before, earlier with warm water soaking hands and/or foot, the reuse nail file is coated with then and puts the external used medicine that the present invention treats tinea unguium on the skin after repairing the sick first of file, helps infiltration of the present invention more, guarantees curative effect.
4, the present invention not only can treat tinea unguium (ash refers to/toenail), can also be used for the treatment of tinea pedis, tinea corporis, tinea versicolor and/or hands tinea; The cure rate of tinea unguium is up to 97%, and the cure rate of tinea pedis, tinea corporis, tinea versicolor and/or the tinea manuum reaches 98%, cures the back and does not have recurrence.
The specific embodiment
The specific embodiment one: the external used medicine of the treatment tinea unguium of present embodiment is to be made up of 21～39 parts povidone iodine, 84～156 parts aspirin, 39～75 parts PEG400,420～780 parts ethanol and 80～149 parts water mixing according to weight portion.
The specific embodiment two: present embodiment with the difference of the specific embodiment one is: the external used medicine of treatment tinea unguium is to be mixed by the water of 24～36 parts povidone iodine, 96～144 parts aspirin, 44～68 parts PEG400,480～720 parts ethanol and 91～137 parts according to weight portion to form.
The specific embodiment three: present embodiment with the difference of the specific embodiment one is: the external used medicine of treatment tinea unguium is to be mixed by the water of 27～33 parts povidone iodine, 108～132 parts aspirin, 50～62 parts PEG400,540～660 parts ethanol and 102～126 parts according to weight portion to form.
The specific embodiment four: present embodiment with the difference of the specific embodiment one is: the external used medicine of treatment tinea unguium is to be mixed by the water of 29～31 parts povidone iodine, 110～130 parts aspirin, 54～58 parts PEG400,560～640 parts ethanol and 105～120 parts according to weight portion to form.
The specific embodiment five: present embodiment with the difference of the specific embodiment one is: the external used medicine of treatment tinea unguium is to be mixed by the water of 30 parts povidone iodine, 120 parts aspirin, 56 parts PEG400,600 parts ethanol and 114 parts according to weight portion to form.
The external used medicine of the treatment tinea unguium of present embodiment, when being used for the treatment of tinea unguium, use warm water soaking after 30 minutes fingernail/toenail earlier, again diseased region is repaiied with nail file and rasped away, medicine with present embodiment spreads upon on fingernail/toenail and the skin on every side thereof then, treat to do the back repaste for the first time once, apply 3～4 layers.When being used for the treatment of tinea corporis, tinea pedis, the tinea manuum and/or tinea versicolor, can directly spread upon clean skin surface.The present invention proves that through over one hundred routine clinical trial the cure rate of tinea unguium reaches 97.0%, and the cure rate of tinea corporis, tinea pedis, the tinea manuum and/or tinea versicolor reaches 98.0%, does not see recurrence and untoward reaction after the healing.
The medicine of present embodiment and the external used medicine of existing treatment tinea unguium are carried out mice Transdermal absorption contrast test, the result shows: the mean transmissivity of the medicine of present embodiment was 1.95% when the transmitance of the medicine of present embodiment was 0.26%, 240 minute in the time of 30 minutes; And the transmitance of the external used medicine of existing treatment tinea unguium is 0 (transmitance=povidone iodine amount of recording/test consumption), illustrates that the drug penetration of present embodiment is good.
Claims (5)
1. external used medicine for the treatment of tinea unguium, the external used medicine that it is characterized in that treating tinea unguium are to be mixed by the water of 24～36 parts povidone iodine, 96～144 parts aspirin, 44～68 parts PEG400,480～720 parts ethanol and 91～137 parts according to weight portion to form.
2. a kind of external used medicine for the treatment of tinea unguium according to claim 1, the external used medicine that it is characterized in that treating tinea unguium are to be mixed by the water of 24～36 parts povidone iodine, 96～144 parts aspirin, 44～68 parts PEG400,480～720 parts ethanol and 91～137 parts according to weight portion to form.
3. a kind of external used medicine for the treatment of tinea unguium according to claim 1, the external used medicine that it is characterized in that treating tinea unguium are to be mixed by the water of 27～33 parts povidone iodine, 108～132 parts aspirin, 50～62 parts PEG400,540～660 parts ethanol and 102～126 parts according to weight portion to form.
4. a kind of external used medicine for the treatment of tinea unguium according to claim 1, the external used medicine that it is characterized in that treating tinea unguium are to be mixed by the water of 29～31 parts povidone iodine, 110～130 parts aspirin, 54～58 parts PEG400,560～640 parts ethanol and 105～120 parts according to weight portion to form.
5. a kind of external used medicine for the treatment of tinea unguium according to claim 1, the external used medicine that it is characterized in that treating tinea unguium are to be mixed by the water of 30 parts povidone iodine, 120 parts aspirin, 56 parts PEG400,600 parts ethanol and 114 parts according to weight portion to form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100639768A CN101229188B (en) | 2008-02-01 | 2008-02-01 | External medicine for onychomycosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100639768A CN101229188B (en) | 2008-02-01 | 2008-02-01 | External medicine for onychomycosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101229188A true CN101229188A (en) | 2008-07-30 |
| CN101229188B CN101229188B (en) | 2010-07-14 |
Family
ID=39896202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100639768A Active CN101229188B (en) | 2008-02-01 | 2008-02-01 | External medicine for onychomycosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101229188B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101693038B (en) * | 2008-10-17 | 2012-06-20 | 吴霜 | Pharmaceutical composition for treating skin (A) disease |
| CN104906127A (en) * | 2015-06-03 | 2015-09-16 | 哈尔滨乐泰药业有限公司 | Povidone iodine compound preparation with enhanced available iodine content stability and preparation method thereof |
| CN105902992A (en) * | 2016-06-28 | 2016-08-31 | 郑州雷曼药业有限公司 | Externally applied medicinal gel for treating onychomycosis and preparation method thereof |
-
2008
- 2008-02-01 CN CN2008100639768A patent/CN101229188B/en active Active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101693038B (en) * | 2008-10-17 | 2012-06-20 | 吴霜 | Pharmaceutical composition for treating skin (A) disease |
| CN104906127A (en) * | 2015-06-03 | 2015-09-16 | 哈尔滨乐泰药业有限公司 | Povidone iodine compound preparation with enhanced available iodine content stability and preparation method thereof |
| CN104906127B (en) * | 2015-06-03 | 2017-11-14 | 哈尔滨快好药业有限公司 | A kind of PVP-I compound preparation of available iodine content stability enhancing and preparation method thereof |
| CN105902992A (en) * | 2016-06-28 | 2016-08-31 | 郑州雷曼药业有限公司 | Externally applied medicinal gel for treating onychomycosis and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101229188B (en) | 2010-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103961636B (en) | Orthopedic disease treatment external application traditional Chinese medicine composition, preparation method and application thereof | |
| CN101229188B (en) | External medicine for onychomycosis | |
| CN101259149A (en) | Tinctura for treating beriberi | |
| CN102526567B (en) | Ointment and medicine composite formula for removing tinea unguium and preparation method thereof | |
| Aziz-Jalali et al. | Efficacy of intralesional bleomycin in the treatment of resistant warts | |
| CN102988277A (en) | Ointment for treating dermatoses such as cutaneous wart, onychomycosis and callus | |
| Mavilia et al. | Effective use of photodynamic therapy on the treatment of chronic leg ulcers: A pilot study. | |
| CN1060955C (en) | Plaster for treating wound | |
| CN100398111C (en) | Powder placed inside shoes for treating foot odor and beriberi | |
| CN100420476C (en) | Collateral-flow-activating external-use medicine of Herba et Radix Inebriantis for treating injuries by falls | |
| CN102178905A (en) | Chinese medicine body surface application therapeutic technology and Chinese medicine combinations | |
| CN1813944A (en) | External-use drug of securidaca inappendiculata hassk for traumatic injury and activating collaterals | |
| CN107050049A (en) | A kind of external application bactericide for treating deep fungal dermatoses | |
| CN101301368B (en) | Medicinal liquor for treating comedo | |
| Wynn et al. | Case report: wound care of a diabetic foot ulcer | |
| CN103768094A (en) | Ointment and medicament combination prescription for removing tinea unguium and preparing methods of ointment and medicament | |
| CN103356847A (en) | Ointment for treating corn and using method thereof | |
| CN101683364B (en) | Skin ointment | |
| CN208372017U (en) | A kind of variable high water proof medical wound application of heat type of chance water | |
| CN104069393A (en) | Ointment for quickly curing wound festering and nonunion as well as preparation method of ointment | |
| CN101700308A (en) | Paste for treating hyperosteogeny | |
| JP3185396U (en) | Kurpaw bark ingredient combination treatment | |
| CN110051690A (en) | A kind of compound medicine for treating tinea pedis and preparation method thereof, application | |
| CN102366448A (en) | Method for preparing beriberi spraying agent | |
| JPH0471891B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: LOCTITE HARBIN PHARMACEUTICAL Co.,Ltd. Assignor: Lang Weijun Contract record no.: 2011230000222 Denomination of invention: External medicine for curing onychomycosis Granted publication date: 20100714 License type: Exclusive License Open date: 20080730 Record date: 20110823 |
|
| ASS | Succession or assignment of patent right |
Owner name: HARBIN LETAI MEDICINE INDUSTRY CO., LTD. Free format text: FORMER OWNER: LANG WEIJUN Effective date: 20130110 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20130110 Address after: 150025 middle section of Beijing Road, Limin Development Zone, Harbin, Heilongjiang Patentee after: LOCTITE HARBIN PHARMACEUTICAL Co.,Ltd. Address before: 150025, Harbin City, Heilongjiang Province Economic and Technological Development Zone in the middle of Beijing Road, Harbin Thai Thai Pharmaceutical Co., Ltd. Patentee before: Lang Weijun |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20171018 Address after: 150001 Zhuhai Road, Limin District, Hulan District, Heilongjiang, Harbin Patentee after: HARBIN KUAIHAO PHARMACEUTICAL CO.,LTD. Address before: 150025 middle section of Beijing Road, Limin Development Zone, Harbin, Heilongjiang Patentee before: LOCTITE HARBIN PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 150001 Zhuhai Road, Limin District, Hulan District, Heilongjiang, Harbin Patentee after: Letai Pharmaceutical Co.,Ltd. Address before: 150001 Zhuhai Road, Limin District, Hulan District, Heilongjiang, Harbin Patentee before: HARBIN KUAIHAO PHARMACEUTICAL Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200702 Address after: 150001 Zhuhai Road, Limin District, Hulan District, Heilongjiang, Harbin Co-patentee after: Heilongjiang Letai Pharmaceutical Co.,Ltd. Patentee after: Letai Pharmaceutical Co.,Ltd. Address before: 150001 Zhuhai Road, Limin District, Hulan District, Heilongjiang, Harbin Patentee before: Letai Pharmaceutical Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 150001 Zhuhai Road, Limin Development Zone, Hulan District, Harbin City, Heilongjiang Province Patentee after: Letai Pharmaceutical Co.,Ltd. Patentee after: Loctite Pharmaceutical (Lanxi) Co.,Ltd. Address before: 150001 Zhuhai Road, Limin Development Zone, Hulan District, Harbin City, Heilongjiang Province Patentee before: Letai Pharmaceutical Co.,Ltd. Patentee before: Heilongjiang Letai Pharmaceutical Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder |